Heartware closes oversubscribed

By Renate Krelle
Thursday, 27 January, 2005

US artificial heart firm Heartware expects to have a market capitalisation of AUD$76.42 million when it lists on the ASX on Monday, having raised US$24.95 million (AUD$32.42 million) in an oversubscribed initial public offering.

The offer incorporates an AUD$5 million US private placement together with an Australian public offer at $0.50 per share.

Heartware is currently preparing a response to a lawsuit issued by Sydney artificial heart firm Ventracor (ASX:VCR) late last year alleging that Heartware's device infringed on the patents underlying Ventracor's ventricular assist device. The response is due by Feburary 7.

Related News

Algae unlocks a more ethical way to grow cells

Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...

Oral drug shows promise for treating Barth syndrome

An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...

New route into cells found for gene therapy viruses

Scientists have identified a previously unknown gateway into human cells — a receptor...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd